Analysis of durable MRD negativity with daratumumab combination treatments for RRMM

Combined analysis of the POLLUX and CASTOR studies found that among patients with relapsed and/or refractory multiple myeloma addition of daratumumab to standard therapies induced higher rates of sustained MRD negativity, which were associated with durable remissions and improved clinical outcomes.